S 179D-hPRLAlternative Names: S179D-hPRL; S179D-prolactin
Latest Information Update: 14 Jan 2003
At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Prolactin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 18 Jan 2001 Preclinical development for Prostate cancer in USA (Unknown route)